| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sebastian J C Neggers, Aart Jan van der Lel. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nature reviews. Endocrinology. vol 5. issue 10. 2009-11-23. PMID:19763127. |
optimal biochemical control cannot be attained by long-acting somatostatin analog monotherapy in a large proportion of patients with acromegaly. |
2009-11-23 |
2023-08-12 |
Not clear |
| Sebastian J C Neggers, Aart Jan van der Lel. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nature reviews. Endocrinology. vol 5. issue 10. 2009-11-23. PMID:19763127. |
combination treatment with somatostatin analogs and pegvisomant (a growth-hormone-receptor antagonist) is, however, highly effective at normalizing the level of insulin-like growth factor i in over 90% of patients and might also have a favorable effect on quality of life in those with biochemically controlled acromegaly. |
2009-11-23 |
2023-08-12 |
Not clear |
| Sebastian J C Neggers, Aart Jan van der Lel. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nature reviews. Endocrinology. vol 5. issue 10. 2009-11-23. PMID:19763127. |
in this review, we discuss the available data on the long-term efficacy and safety of somatostatin analog-pegvisomant combination treatment and its potential use in patients with acromegaly. |
2009-11-23 |
2023-08-12 |
Not clear |
| João Paulo C Almeida, Lucas Alverne F Albuquerque, Camila L H Ferraz, Italo Mota, Jackson Gondim, Tânia M B L Ferra. McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. Arquivos brasileiros de endocrinologia e metabologia. vol 53. issue 1. 2009-11-12. PMID:19347192. |
mccune-albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. |
2009-11-12 |
2023-08-12 |
Not clear |
| Steven W J Lamberts, Leo J Hoflan. Future treatment strategies of aggressive pituitary tumors. Pituitary. vol 12. issue 3. 2009-10-20. PMID:19003539. |
in acromegaly, the existing somatostatin analogs, octreotide and lanreotide, will remain the medical treatment of choice for the foreseeable future. |
2009-10-20 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Mariano Galdiero, Gaetano Lombardi, Rosario Pivonell. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. The Journal of clinical endocrinology and metabolism. vol 94. issue 10. 2009-10-20. PMID:19622615. |
effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-i levels, tumor shrinkage, and cardiovascular disease: a prospective study. |
2009-10-20 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Mariano Galdiero, Gaetano Lombardi, Rosario Pivonell. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. The Journal of clinical endocrinology and metabolism. vol 94. issue 10. 2009-10-20. PMID:19622615. |
the objective of the study was to evaluate the efficacy of 5 yr of depot somatostatin analogs (ssas) as first-line therapy in acromegaly. |
2009-10-20 |
2023-08-12 |
Not clear |
| b' Joice Valentim, Vanessa Passos, Fabio Mataveli, Alessandra Calabr\\xc3\\xb. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arquivos brasileiros de endocrinologia e metabologia. vol 52. issue 9. 2009-10-16. PMID:19197453.' |
cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in brazil. |
2009-10-16 |
2023-08-12 |
Not clear |
| b' Joice Valentim, Vanessa Passos, Fabio Mataveli, Alessandra Calabr\\xc3\\xb. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arquivos brasileiros de endocrinologia e metabologia. vol 52. issue 9. 2009-10-16. PMID:19197453.' |
this study aims to compare economic and patient impacts of the treatment of acromegaly with two different somatostatin analogues (octreotide lar and lanreotide sr) in brazil. |
2009-10-16 |
2023-08-12 |
Not clear |
| Agata Bałdys-Waligórska, Filip Gołkowski, Anna Krzentowska, Grzegorz Sokołowski, Alicja Hubalewska-Dydejczy. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation]. Przeglad lekarski. vol 66. issue 5. 2009-10-13. PMID:19739577. |
since acromegaly is associated with high rates of comorbidities and increased mortality risk compared to the general population, over the last few years somatostatin analogues have been used to treat acromegaly patients who, following surgery, have not fulfilled cure criteria (basal hgh < 2.5 ng/ml, igf-1 below normal ranges for age and sex and hgh < 1.0 ng/ml in the 120th min of the ogtt test). |
2009-10-13 |
2023-08-12 |
Not clear |
| Leonardo Vieira Neto, Giselle Fernandes Taboada, Mônica Roberto Gadelh. Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly. Arquivos brasileiros de endocrinologia e metabologia. vol 52. issue 8. 2009-10-07. PMID:19169483. |
somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide lar responsiveness in acromegaly. |
2009-10-07 |
2023-08-12 |
Not clear |
| M Ozbek, M Erdogan, E Akbal, G Gönülala. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 117. issue 7. 2009-10-01. PMID:18841538. |
the use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. |
2009-10-01 |
2023-08-12 |
Not clear |
| Marily Theodoropoulou, Maria A Tichomirowa, Caroline Sievers, Alexander Yassouridis, Thomas Arzberger, Olivier Hougrand, Manuel Deprez, Adrian F Daly, Patrick Petrossians, Uberto Pagotto, Albert Beckers, Günter K Stall. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. International journal of cancer. vol 125. issue 9. 2009-09-15. PMID:19637311. |
tumor zac1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. |
2009-09-15 |
2023-08-12 |
Not clear |
| G Lombardi, F Minuto, G Tamburrano, M R Ambrosio, G Arnaldi, M Arosio, V Chiarini, R Cozzi, S Grottoli, F Mantero, F Bogazzi, M Terzolo, P Tita, P F Boscani, A Cola. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. Journal of endocrinological investigation. vol 32. issue 3. 2009-09-02. PMID:19542735. |
efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in somatostatin analogue-naive patients with acromegaly. |
2009-09-02 |
2023-08-12 |
Not clear |
| G Lombardi, F Minuto, G Tamburrano, M R Ambrosio, G Arnaldi, M Arosio, V Chiarini, R Cozzi, S Grottoli, F Mantero, F Bogazzi, M Terzolo, P Tita, P F Boscani, A Cola. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. Journal of endocrinological investigation. vol 32. issue 3. 2009-09-02. PMID:19542735. |
to evaluate efficacy and safety of lanreotide autogel (atg) 120 mg injections every 4-8 weeks in somatostatin analogue-naïve patients with acromegaly. |
2009-09-02 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Ferdinand Roelfsema, Alberto M Pereira, Johannes A Romij. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert review of pharmacoeconomics & outcomes research. vol 9. issue 3. 2009-08-31. PMID:19527094. |
we used the following assumptions: after the diagnosis of acromegaly there is a mean remaining lifespan of approximately 33 years; the success rates of surgery and somatostatin analogues in controlling the disease are approximately 60%; and the lifelong costs of different algorithms to control acromegaly in 100 patients ranged from 43 million euros (primary surgery and secondary somatostatin analogues) to 57 million euros (primary somatostatin analogues and secondary surgery) and even reached 95 million euros (medical treatment only). |
2009-08-31 |
2023-08-12 |
Not clear |
| Agnes Mondok, Miklós Tóth, Attila Patócs, Nikolette Szücs, Péter Igaz, Péter Pusztai, Sándor Czirják, Gabriella Beko, Edit Gláz, Károly Rácz, Zsolt Tulassa. [Outcome of somatostatin analogue treatment in acromegaly]. Orvosi hetilap. vol 150. issue 31. 2009-08-28. PMID:19617182. |
[outcome of somatostatin analogue treatment in acromegaly]. |
2009-08-28 |
2023-08-12 |
Not clear |
| Agnes Mondok, Miklós Tóth, Attila Patócs, Nikolette Szücs, Péter Igaz, Péter Pusztai, Sándor Czirják, Gabriella Beko, Edit Gláz, Károly Rácz, Zsolt Tulassa. [Outcome of somatostatin analogue treatment in acromegaly]. Orvosi hetilap. vol 150. issue 31. 2009-08-28. PMID:19617182. |
during the past decade the importance of medical therapy, especially treatment with somatostatin analogues has increased significantly in patients with active acromegaly. |
2009-08-28 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Silvia Savastano, Mariano Galdiero, Ludovica F S Grasso, Gaetano Lombardi, Rosario Pivonell. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. The Journal of clinical endocrinology and metabolism. vol 94. issue 8. 2009-08-25. PMID:19491229. |
glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. |
2009-08-25 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Silvia Savastano, Mariano Galdiero, Ludovica F S Grasso, Gaetano Lombardi, Rosario Pivonell. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. The Journal of clinical endocrinology and metabolism. vol 94. issue 8. 2009-08-25. PMID:19491229. |
the objective of the study was to investigate the impact of first-line somatostatin analogs (ssas) on glucose tolerance (gt) in acromegaly. |
2009-08-25 |
2023-08-12 |
Not clear |